Quercetin, luteolin, linolenic acid, adenosine, kaempferol, etc., were considered the potential core compounds, and PTGS2, ESR1, PTGS1, NOS2, AKT1, etc. were the main potential targets of BSYQ for asthma and IPF therapy. This evidence concerns the gene AKT1 and asthma.